Cullinan Therapeutics reports REZILIENT3 PFS improvement
Cullinan Therapeutics said zipalertinib plus chemotherapy produced a median progression-free survival of 14.5 months versus 8.5 months in the Phase 3 REZILIENT3 trial.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.